Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $70,729.32 in Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) Director Gilla Kaplan sold 6,814 shares of the firm's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $10.38, for a total transaction of $70,729.32. Following the transaction, the director now owns 37,809 shares in the company, valued at $392,457.42. This represents a 15.27% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Gilla Kaplan also recently made the following trade(s):

• On Friday, June 13th, Gilla Kaplan sold 15,000 shares of Tyra Biosciences stock. The stock was sold at an average price of $10.31, for a total transaction of $154,650.00.
• On Thursday, June 12th, Gilla Kaplan sold 30,000 shares of Tyra Biosciences stock. The shares were sold at an average price of $10.31, for a total value of $309,300.00.

Tyra Biosciences Trading Down 0.9%

Tyra Biosciences stock traded down $0.09 on Thursday, reaching $9.50. 157,815 shares of the stock were exchanged, compared to its average volume of 279,892. Tyra Biosciences, Inc. has a twelve month low of $6.42 and a twelve month high of $29.60. The firm has a fifty day moving average price of $9.70 and a two-hundred day moving average price of $11.85. The stock has a market cap of $504.36 million, a PE ratio of -5.83 and a beta of 1.07.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. Equities analysts anticipate that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Tyra Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. KLP Kapitalforvaltning AS acquired a new position in Tyra Biosciences during the 4th quarter valued at $31,000. US Bancorp DE acquired a new stake in Tyra Biosciences in the 4th quarter worth $50,000. BNP Paribas Financial Markets bought a new position in shares of Tyra Biosciences during the 4th quarter worth about $60,000. Aquatic Capital Management LLC acquired a new position in shares of Tyra Biosciences during the fourth quarter valued at about $64,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Tyra Biosciences during the first quarter valued at about $84,000. Institutional investors and hedge funds own 84.14% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on TYRA. Piper Sandler began coverage on Tyra Biosciences in a research note on Wednesday, May 21st. They set an "overweight" rating and a $33.00 price target for the company. HC Wainwright restated a "buy" rating and issued a $30.00 target price on shares of Tyra Biosciences in a report on Monday, March 31st. Finally, Wedbush reaffirmed an "outperform" rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Friday, March 28th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $30.83.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.